Accenture: makes an investment in 1910 Genetics

(CercleFinance.com) - Accenture has invested, through Accenture Ventures, in 1910 Genetics, a biotech company advancing small and large molecule drug discovery through an AI platform.


As part of this investment, Accenture and 1910 will collaborate to help clients in the biopharmaceutical industry accelerate drug target identification, reduce costs and deliver better, more affordable therapies to patients.

1910's proprietary Input-Transform-Output platform is a scalable, end-to-end AI solution designed to deliver better drug candidates with applications across all modalities and therapeutic areas.

The platform enables drug discovery teams to identify high-precision targets, optimize molecule design and conduct advanced simulations throughout the R&D process.

'By facilitating data-driven decision-making, it can increase the likelihood of clinical success, while shortening experimental iteration cycles and reducing the overall cost of drug development' explains the group.

' It is essential to adopt an AI-driven approach to reinvent the drug discovery and development process', said Tom Lounibos, global head of Accenture Ventures.

Copyright (c) 2024 CercleFinance.com. All rights reserved.